Clinical trials: Peritoneum Cancer
Colorectal Cancer, Metastatic Cancer
Gene Expression Profiling in Normal Tissue and Tumor Tissue From Patients With Colon Cancer That Has Spread to the Liver, Lungs, or Peritoneum
RATIONALE: Studying the genes expressed in samples of tissue from patients with cancer may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00896753
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
This phase II trial is studying how well depsipeptide (romidepsin) works in treating patients with recurrent ovarian epithelial or peritoneal cavity cancer.
- Trial name
- NCT00091195
- Testing
- romidepsin
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003345
- Testing
- cisplatin, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Primary Peritoneal Cancer
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02278783
- Testing
- regorafenib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Peritoneal Carcinomatosis
Prospective Intraperitoneal Chemotherapy in Carcinomatosis Cohort Study
Evaluation of clinical outcome and economical aspects in the treatment of patients with peritoneal carcinomatosis.
- Trial name
- NCT03124394
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Kantonsspital Winterthur KSW
Carcinoma, Peritoneal Neoplasm
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis
Two days prior to planned surgery, paclitaxel is infused IV over 24 hours. Patients will undergo cytoreductive surgery, to debulk tumor.
- Trial name
- NCT00001569
- Testing
- Cisplatin, Paclitaxel, 5-FU
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT02068794
- Testing
- Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Epithelial ovarian cancer (EOC) is the leading cause of gynecological malignancy-related deaths worldwide and is a substantial health threat to women.
- Conditions
- Ovarian Neoplasms Malignant (Excl Germ Cell), Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- Trientine (NCT03480750)
- Testing
- trientine dihydrochloride, pegylated liposomal doxorubicin, carboplatin
- Volunteers
- 18 people
- Sponsor
- National Cheng-Kung University Hospital
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
This phase I trial studies the side effects of hyperthermic intraepithelial chemotherapy with cisplatin after surgery or cisplatin before surgery in treating patients with stage III or IV ovarian, fallopian tube or peritoneal…
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT05415709
- Testing
- Carboplatin, Cisplatin, Cytoreductive Surgery
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ovarian Cancer, Fallopian Tube Cancer
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
The main purpose of this study is to begin to collect information and try to learn whether or not the combination of oxaliplatin, gemcitabine and bevacizumab works in treating women with recurrent mullerian carcinoma.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00418093
- Testing
- Gemcitabine, Oxaliplatin, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Dana-Farber Cancer Institute
Ovarian Cancer, Fallopian Tube Cancer
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
This study is researching an investigational drug called REGN5668 : alone or, combined with cemiplimab (also known as REGN2810) or, combined with both cemiplimab and fianlimab (also known as REGN3767), or combined with ubamatamab…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Trial name
- NCT04590326
- Testing
- REGN5668, Cemiplimab, Ubamatamab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 612 people
- Sponsor
- Regeneron Pharmaceuticals
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum…
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
- Trial name
- NCT00421889
- Testing
- belinostat, Paclitaxel, Carboplatin
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 80 people
- Sponsor
- Valerio Therapeutics
Fallopian Tube Cancer, Ovarian Cancer
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating women who have refractory or relapsed ovarian epithelial…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005025
- Testing
- herpes simplex thymidine kinase, ganciclovir
- Where
- United States
- Sponsor
- John Stoddard Cancer Center at Iowa Methodist Medical Center
Ovarian Cancer, Fallopian Tube Cancer
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
This is a multicenter, randomized, blinded, 3-arm Phase 3 study to evaluate the efficacy and safety of Fluzoparib alone or with Apatinib versus Placebo, as maintenance treatment, in patients with Stage III or IV ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT04229615
- Testing
- Fluzoparib; Apatinib, Fluzoparib
- Where
- China
- Volunteers
- 690 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Ovarian Neoplasms, Peritoneal Neoplasms
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary…
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01932125
- Testing
- Bevacizumab
- Where
- 13 sites in India
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Epithelial Ovarian Cancer, Peritoneal Cancer
LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer
This is a pilot feasibility study assessing the use of a commercial molecular profiling service in the UK's National Health Service (NHS).
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Gynaecological Malignancy
- Trial name
- NCT02668913
- Testing
- Diagnostic analysis
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Geoff Hall
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00407758
- Testing
- enzastaurin hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 28 people
- Sponsor
- Gynecologic Oncology Group
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
This study is a multicenter, randomized, controlled, open-label, phase II study to evaluate the efficacy and safety of SG001 in combination with doxorubicin hydrochloride liposome injection in patients with platinum-resistant…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT04983550
- Testing
- SG001, Doxorubicin hydrochloride liposome injection
- Volunteers
- 126 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Anxiety, Fatigue
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
This clinical trial studies the quality of life and care needs of patients with persistent or recurrent ovarian cancer, fallopian tube cancer, or peritoneal cancer.
- Conditions
- Anxiety, Fatigue, Nausea and Vomiting, Neurotoxicity Syndrome
- Trial name
- NCT01372787
- Testing
- Assessment of Therapy Complications, Medical Chart Review, Quality-of-Life Assessment
- Where
- 144 sites in United States
- Volunteers
- 103 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
This is a randomized Phase I/II study designed to assess the induction of an anti-tumor immune response; the effect of cyclophosphamide on the vaccine; and to assess safety in subjects with advanced ovarian cancer or primary…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- DC-Ova (NCT00478452)
- Testing
- DC-Ova, DC Ova with Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Pennsylvania
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.